Skip to main content
. 2011 Oct 26;118(26):6920–6929. doi: 10.1182/blood-2011-08-368225

Figure 3.

Figure 3

Survival of older CN-AML patients in the ELN Favorable and ELN Intermediate-I genetic groups, according to ASXL1 mutation status. (A) OS of ELN Favorable group patients. (B) OS of ELN Intermediate-I group patients. (C) EFS of ELN Favorable group patients. (D) EFS of ELN Intermediate-I group patients. ELN Fav. indicates ELN Favorable category; and ELN Int.-I, ELN Intermediate-I category.